22.03.2012 • News

Evonik Breaks Ground on New Organics Production Facility in Shanghai

Evonik Industries broke ground to mark the official start of the construction for its multimillion-euro investment in Shanghai.

At the ceremony, Klaus Engel, chairman of the Evonik executive board, said, "This investment is in line with our priority to expand our business in the emerging markets."

The plant is expected to be operational in 2013. It will supply innovative ingredients and specialty surfactants based on renewable raw materials for the personal care, household care and industrial specialties industry. It will serve markets primarily in China and Asia Pacific, with an annual capacity of 80 kt.

The new production plant will be built at Evonik's multi-user site in Shanghai Chemical Industry Park, which is in the Yangtze River Delta Economic Zone.

Parallel to the construction of the new production plant, Evonik is expanding its R&D center at its Xinzhuang site in Shanghai, with an investment of €23 million.The expansion includes laboratories for research and development, application technology, and technical service, with aims to develop product applications and provide technology service for customers throughout China and Asia Pacific.

Company

Logo:

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany

Company contact







From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read